E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the dose response and efficacy of a range of once daily doses of GSK189075 versus placebo on the change from baseline in HbA1c. |
|
E.2.2 | Secondary objectives of the trial |
•To evaluate, alongside once daily dosing, the efficacy of one bid dose of GSK189075 and 30mg pioglitazone versus placebo, on the change from baseline in HbA1c. •To evaluate the safety and tolerability of a range of qd doses of GSK189075 versus placebo alongside one bid dose of GSK189075 and 30mg pioglitazone. •To evaluate the effect of a range of qd doses of GSK189075 versus placebo, and alongside one bid dose of GSK189075 and 30mg pioglitazone, on additional glycemic/PD parameters. •To evaluate the effect of a range of qd doses of GSK189075 versus placebo, and alongside one bid dose of GSK189075 and 30mg pioglitazone on body weight
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects eligible for enrollment in the study must meet all of the following criteria: 1. Subjects with a documented diagnosis of T2DM and HbA1c ≥7.5% and ≤9.5% measured by the central laboratory at Visit 1 and Visit 2. 2. Subjects who are treatment-naïve and have taken ≤2 weeks of insulin or ≤4 weeks of any oral anti-diabetic agent in the past 12 months, but not at all within the 3 months prior to screening or subjects who are newly diagnosed and have been treated with diet and exercise for a minimum of 8 weeks. 3. Subjects who are 18 to 70 years of age inclusive at the time of Screening. 4. Eligible females must be of non-childbearing potential (i.e., females regardless of age who are surgically sterile (i.e., documented total hysterectomy or bilateral oophorectomy) or females who are post-menopausal (i.e., no menstrual period for a minimum of 12 consecutive months). All females must have a negative urine pregnancy test on the day of, and prior to randomization. Note: In questionable cases, a blood sample for follicle stimulating hormone (FSH) >40 MIU/mL and estradiol <40pg/mL (<140 pmol/L) may be obtained at screening, at the discretion of the investigator to confirm post-menopausal state. 5. Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed.
|
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following criteria must not be enrolled in the study: 1.Metabolic Disease •Diagnosis of Type 1 diabetes mellitus. •History of ketoacidosis which has required hospitalization. •Thyroid disorder •TSH <0.4 MIU/L (<0.4 MCIU/mL) or >5.5 mIU/L (>5.5 MCIU/mL) at Screening. Note: Hypothyroidism treated with the same dose and regimen of thyroid hormone replacement for at least 3 months prior to Screening is allowed. •BMI of <25 kg/m2 or >40 kg/m2. •Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening 2.Diabetic Medication •Has taken insulin for >2 weeks in the 12 months prior to screening or at any time within the 3 months prior to screening. •Has taken any oral anti-diabetic medication for more than 4 weeks in the 12 months prior to screening or at anytime within the 3 months prior to screening. 3.Cardiovascular Disease Recent history or presence of clinically significant acute cardiovascular disease including: •Documented myocardial infarction in the 6 months prior to Screening. •Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening. •Unstable angina in the 6 months prior to Screening. •Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis. •Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment or the NYHA Class criteria in accordance with the local prescribing information for pioglitazone. •Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 3 months prior to Screening. •Based on local readings, the subject has an initial QTc interval (Bazett’s) ≥450msec at Screening, and after two additional ECGs taken 5 minutes apart, the average of the QTC interval from the three ECGs is ≥450msec. •Other clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of efficacy or safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity. •Fasting triglycerides ≥400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 3 months prior to Screening. Niacin and bile acid sequestrants are prohibited. 4.Hepatic Disease Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including: Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening. •alanine aminotransferase (ALT) •aspartate aminotransferase (AST) •alkaline phosphatase (AP) Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert’s disease. 5.Pancreatic Disease •Secondary causes of diabetes: •history of chronic or acute pancreatitis 6.Renal Disease Significant renal disease at Screening as manifested by: •lomerular filtration rate (GFR) <60mL/min (as calculated by Quest at Visit using the Modification of Diet in Renal Disease (MDRD) equation as follows: GFR (mL/min/1.73m2) = 186 x (serum creatinine mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.120 if African American). •≥1+ protein on urine dipstick •Trace or ≥1+ leukocyte esterase on urine dipstick •Trace or ≥1+ blood on urine dipstick •Positive nitrite on urine dipstick •Recurrent genitourinary tract infections defined as ≥2 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening. 7.Concurrent Disease •Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), ECG, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity. •History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.). •History of malignancy within the past 5 years other than superficial squamous cell carcinoma (non-invasive on pathology) or basal cell carcinoma (successfully treated with local excision). •History of cervical cancer in situ treated definitively at least 6 months prior to Screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the change from baseline (Week 0) in HbA1c at Week 12 for GSK189075 dosed once daily compared to placebo. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 20 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 20 |